March 30 (Reuters) - Neovacs Sa:
* FY OPERATING LOSS EUR 18.3 MILLION VERSUS LOSS OF EUR 17.3 MILLION YEAR AGO
* FY REVENUE EUR 0.8 MILLION VERSUS EUR 0.4 MILLION YEAR AGO
* FY NET LOSS EUR 14.8 MILLION VERSUS LOSS OF EUR 13.9 MILLION YEAR AGO
* BASED ON POSITIVE OUTCOME OF IFN-ALPHA KINOID LUPUS STUDY, INTENDS TO FILE FOR ORPHAN DRUG DESIGNATION IN SOUTH KOREA WITH CKD IN 2018
* ELIGIBLE TO RECEIVE MILESTONE PAYMENTS IN H2 FROM 3 INTERNATIONAL PARTNERS, PENDING POSITIVE RESULTS OF IFN-ΑLPHA KINOID PHASE IIB CLINICAL TRIAL IN LUPUS
* NEOSTELL PROJECT EXPECTED TO START IN H2 2018 AND BE COMPLETED IN 2023
* AT DEC. 31, 2017, NEOVACS HAD CASH AND CASH EQUIVALENTS OF EUR 5.1 MILLION
* EXPECTS TO REPORT RESULTS OF PHASE IIB CLINICAL TRIAL IN LUPUS IN MID-2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
